Phaseline

Targets › POLG

POLG (DNA polymerase subunit gamma-1): drug programs, companies and trials

8 programs from 7 companies in 27 trials: 11 Phase 3, 10 Phase 2, 5 Phase 4, 1 Phase 1; Infectious disease, Oncology, Neurology; next expected readout Dec 2026.

Catalytic subunit of DNA polymerase gamma solely responsible for replication of mitochondrial DNA (mtDNA). Replicates both heavy and light strands of the circular mtDNA genome using a single-stranded DNA template, RNA primers and the four deoxyribonucleoside triphosphates as substrates. (UniProt, P54098)

Open in Phaseline: the race on POLG, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Bangladesh Medical UniversityEntecavir
DNA polymerase/reverse transcriptase inhibitor
POLGPhase 4Hepatitis BJan 2027
University Health Network, TorontoEntecavir
DNA polymerase/reverse transcriptase inhibitor
POLGPhase 4Hepatitis B Virus (HBV)Aug 2027
ANRS, Emerging Infectious DiseasesTenofovir Disoproxil Fumarate (TDF)
Nucleotide reverse transcriptase inhibitor (NtRTI) - inhibits HBV reverse transcriptase
POLGPhase 4Hepatitis B Virus - Chronic ActiveAug 2027
Sun Yat-sen UniversityEntecavir
DNA polymerase/reverse transcriptase inhibitor
POLG, POLBPhase 3Gastrointestinal Cancers; Resolved Hepatitis BDec 2026
Merck & Co. (MSD)Islatravir
Reverse transcriptase inhibitor; Human immunodeficiency virus type 1 reverse transcriptase inhibitor
POLG, RTPhase 3HIV-1 Infection; HIV Infection; Human Immunodeficiency Virus Type 1 (HIV-1) InfectionAug 2027
Merck & Co. (MSD)Doravirine
Human immunodeficiency virus type 1 reverse transcriptase negative allosteric modulator
RT, POLA2, POLGPhase 3HIV-1 Infection; Human Immunodeficiency Virus (HIV) Infection; HIV-1-infection; HIV …Jul 2028
National Institute of Allergy and Infectious Diseases (NIAID)Tenofovir alafenamide (TAF)
Nucleotide reverse transcriptase inhibitor (NtRTI), prodrug of tenofovir
POLGPhase 2Healthy VolunteerJan 2028
National University Hospital, SingaporeDescovy (TAF/FTC)
Combination reverse transcriptase inhibitor - nucleotide RTi (TAF) and nucleoside RTi (FTC
POLGPhase 1Mild Cognitive Impairment (MCI)–

Conditions

HIV-1 Infection (6) HIV-1-infection (4) Human Immunodeficiency Virus Type 1 (HIV-1) Infection (2) Human Immunodeficiency Virus (HIV) Infection (2) Healthy Volunteer (2) Gastrointestinal Cancers (1) Resolved Hepatitis B (1) HIV Infection (1) Hepatitis B (1) Hepatitis B Virus (HBV) (1) HIV (1) HIV - Human Immunodeficiency Virus (1)

Modalities

small molecule (7), mixed (1)

Companies

Merck & Co. (MSD) (2) Sun Yat-sen University (1) Bangladesh Medical University (1) University Health Network, Toronto (1) National University Hospital, Singapore (1) National Institute of Allergy and Infectious Diseases (NIAID) (1) ANRS, Emerging Infectious Diseases (1)

Related targets

RT (2) POLB (1) POLA2 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.